CEPI

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Retrieved on: 
Thursday, March 21, 2024
Control, EST, Congress, Lyme disease, CEPI, Coalition, Saint-Herblain, Pan American Health Organization, Walter, PAHO, International Vaccine Institute, Chikungunya, Epidemic, Drug, IVI, CDC, Process, VLA, Euronext Paris, Market access, ACIP, The 24th

The Company will have a display in the exhibit area of the congress at booth #433.

Key Points: 
  • The Company will have a display in the exhibit area of the congress at booth #433.
  • There will be two sessions, from 11:40 to 12:20 EST and again from 12:30 to 1:10pm EST.
  • Advisory Committee on Immunization Practices (ACIP)1 and these recommendations were adopted by the Centers for Disease Control and Prevention (CDC)2.
  • Additionally, Valneva CEO Thomas Lingelbach will present the Best Production / Process Development award at the event.

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Retrieved on: 
Wednesday, March 20, 2024
MERS, Patient, Ethics, Epidemic, NUC, Group 3, Clinical trial, Liver, Depreciation, Vaccine, Hepatitis, PD-1, Research, Coalition, Arbutus, Hepatology, Coeliac disease, Nivolumab, Safety, Immune system, CHB, Prostate cancer, CEPI, AASLD, University, Șaeș, Cancer, HBV, Conference, AstraZeneca, Autoimmunity, Infection, Human papillomavirus infection, Oxford University Innovation, SNAP, HPV, APOLLO, Pharmaceutical industry

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

Key Points: 
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • We presented the final data in June 2023 at the European Association for the Study of the Liver Congress 2023 – The International Liver CongressTM.
  • We presented this data during an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
  • In November 2023, we announced the company’s renaming as Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.

TechInvention Lifecare announces the ground breaking of its state-of-the-art Global Collaborative Centre for Medical Countermeasures

Retrieved on: 
Wednesday, February 28, 2024
CEPI, GMP, Global health, One Health, GCMC, Environmental health, Organization, IP, WHO, Research, Vaccine

MUMBAI, INDIA, Feb 28, 2024 - (ACN Newswire) - In a significant stride towards enhancing global health security and pandemic preparedness, TechInvention Lifecare Pvt.

Key Points: 
  • MUMBAI, INDIA, Feb 28, 2024 - (ACN Newswire) - In a significant stride towards enhancing global health security and pandemic preparedness, TechInvention Lifecare Pvt.
  • Ltd. is proud to announce the ground breaking of its Global Collaborative Centre for Medical Countermeasures (GCMC) with an investment of approx.
  • The centre is strategically located close to the upcoming international airport in Navi Mumbai, India.
  • GCMC has been acknowledged for its global significance at the 2nd World Local Production Forum in The Hague on 6-8 November 2023, organized by the WHO.

IQVIA Publishes its 2023 Environmental, Social and Governance Report

Retrieved on: 
Monday, February 26, 2024
Technology, Pharmaceutical, Health Technology, Environmental, Social and Governance (ESG), Health Insurance, Oncology, Artificial Intelligence, Environment, Research, Medical Devices, Infectious Diseases, Clinical Trials, Environmental Policy, Biotechnology, Professional Services, Health, Recycling, Practice Management, Managed Care, Data Analytics, Science, Climate Change, Sustainability, Data Management, RSV, Woman, Coalition, Investment, Targets, Social, Epidemic, CEPI, ESG, Annual report, Health care, Pharmacy, Patient, Science Based Targets initiative, Plastic, Survival, Lung cancer, Diagnosis, IQV, Workforce, GHG, Public, Management

IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.

Key Points: 
  • IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.
  • “We are proud that we delivered on our sustainability commitments despite the tumultuous macro-environment we have been operating in.”
    IQVIA’s full 2023 ESG report can be downloaded here .
  • We established our dedicated global public health business in 2023, which now works with more than 75 clients across the globe.
  • For the third year in a row, IQVIA was named the number one most admired company in our category, Healthcare: Pharmacy and Other Services.

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Retrieved on: 
Wednesday, January 24, 2024
Speech, Therapy, Research, Nasopharyngeal carcinoma, Summit, IIT, NKT, AI, Government, EMA, BioNTech, CureVac, Cancer, Acquisition, WHO, Drug development, Safety, Intellectual property, Toxicity, Patent, Merck, Messenger, HBV, LNP, Vaccine, Colorectal cancer, CEPI

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.

Key Points: 
  • CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
  • The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
  • Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.
  • This project, along with its extensive pipeline, positions WestGene at the forefront of biopharmaceutical innovation and research.

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Retrieved on: 
Wednesday, January 24, 2024
Speech, Therapy, Research, Nasopharyngeal carcinoma, Multimedia, Summit, IIT, NKT, AI, Government, EMA, BioNTech, CureVac, Cancer, Acquisition, WHO, Drug development, Safety, Intellectual property, Toxicity, Patent, Merck, Messenger, HBV, LNP, Vaccine, Colorectal cancer, CEPI

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.

Key Points: 
  • CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
  • Renowned for her pivotal role in mRNA research, Dr. Xiangrong Song, co-founder and CEO of WestGene, presented the latest advances in the company's oncology sector, with a special focus on mRNA-based cancer vaccines.
  • The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
  • Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.

CEPI Partners With Lemonex to Advance mRNA Vaccine Delivery Against Future Pandemic Threats

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, RNA, LNP, Disease, Partnership, Risk, Multimedia, Messenger, South Korea, Vaccine, CEPI, Vaccination, Clinical trial, Infection, Temperature, Seoul National University Hospital, Safety, Policy

CEPI has partnered with Lemonex Inc. (Lemonex), a biotechnology company in the Republic of Korea, to advance their mRNA drug delivery technology, DegradaBALL®, which has the potential to both minimise post-mRNA vaccination side effects and improve access to future mRNA vaccines.

Key Points: 
  • CEPI has partnered with Lemonex Inc. (Lemonex), a biotechnology company in the Republic of Korea, to advance their mRNA drug delivery technology, DegradaBALL®, which has the potential to both minimise post-mRNA vaccination side effects and improve access to future mRNA vaccines.
  • (Photo: Lemonex Inc.)
    CEPI is providing Lemonex up to US $4.6 million in funding to evaluate the safety of the DegradaBALL® mRNA vaccine platform in a Phase I clinical study taking place at Seoul National University Hospital.
  • The funding will also support the development of a freeze-dried formulation to reduce complex-cold chain vaccine storage requirements and increase the use of mRNA vaccines in the Global South.
  • Dr. Richard Hatchett, CEO of CEPI, said: “Clinically validated for the first time during the COVID-19 pandemic, mRNA vaccines will be critical if we are to accelerate our responses to future infectious disease threats.

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event

Retrieved on: 
Monday, December 11, 2023
Biophysical environment, Patient, Epidemic, Science, Partnership, Culture, Virus, Messenger, Vaccine, Access, Health, ESG, CEPI, Disclosure, Coalition, Social, MRNA, Public, Global health, Organization, Corporation, Environment

We look forward to building on our substantial ESG progress to become the best version of Moderna."

Key Points: 
  • We look forward to building on our substantial ESG progress to become the best version of Moderna."
  • Within its clinical trials, Moderna believes a committed approach to offering equal healthcare accessibility is achievable and necessary.
  • Governance & Ethics: Moderna prioritizes accountability and transparency around its ESG efforts, including through the publication of its second annual ESG report and continued commitment to disclosing key metrics.
  • To register for the live webcast of Moderna's ESG Investor Event, visit https://moderna-esg-day-2023.open-exchange.net/registration.

New partnership aims to advance vaccine against MERS coronavirus

Retrieved on: 
Thursday, December 21, 2023
Epidemic, Partnership, Immune system, University of Oxford, Infection, PRIME, EMA, Urinary tract infection, Barinthus, WHO, Oxford–AstraZeneca COVID-19 vaccine, Vaccine, MERS, MERS-related coronavirus, CEPI, Vaccination, Coalition, Clinical trial, Cancer, University, ChAdOx1, COVID-19, European Medicines Agency, Policy, Public, Coronavirus, Phase II, Medicine, Public health, Autoimmunity, Pharmaceutical industry

“We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS.

Key Points: 
  • “We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS.
  • “There is an active need for a MERS vaccine for at-risk populations and travellers in the Middle East.
  • MERS is a severe respiratory infection caused by MERS-CoV, a coronavirus that was first identified in 2012 in Saudi Arabia.
  • The vaccine will be made available to low- and middle-income countries at a price no higher than the cost of manufacturing plus 10 percent.

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

Retrieved on: 
Monday, December 18, 2023
RNA, Entrepreneurship, Epidemic, Partnership, Pasteur Institute, Government, State, African, Messenger, Research, WHO, Excellency, Vaccine, Mortality, Quality control, BNTX, CEPI, Republic, Coalition, Laboratory, BioNTech, COVID-19, HIV, Tuberculosis, World Health Organization, Mpox, Infection, Child

President Paul Kagame of Rwanda, Heads of State and Government from Africa and around the world, leadership of the African Union and European Union, as well as from WHO, Africa CDC and CEPI attended the official inauguration of the BioNTech site in Kigali

Key Points: 
  • President Paul Kagame of Rwanda, Heads of State and Government from Africa and around the world, leadership of the African Union and European Union, as well as from WHO, Africa CDC and CEPI attended the official inauguration of the BioNTech site in Kigali
    KIGALI, Rwanda, December 18, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) has reached the next milestone in the establishment of mRNA vaccine manufacturing capacities in Africa with the inauguration of the Company’s site in Kigali, Rwanda.
  • The Company’s manufacturing site in Kigali could become the first commercial-scale mRNA manufacturing facility on the continent.
  • In 2024, BioNTech expects to complete all buildings on site, including a warehouse, offices and laboratories for quality control.
  • BioNTech plans to conduct clinical trials in Africa for vaccine candidates against malaria, tuberculosis and HIV in 2024.